REFERENCES
- Motzer RJ, Hutson TE, Tomczak P, Louie SG, Michaelson MD, Bukowski RM, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115–124
- Escudier B, Pluzanska A, Karalewski P, Ravaud A, Brac-arda S, Szczylik C, et al. Bevacizumab plus interferon alfa-2b for the treatment of metastatic renal cell carcinoma: a randomized, double-blind phase III trial. Lancet 2007; 370: 2103-2111.
- Bhojani N, Jeldres C, Patard JJ, Perrotte P, Suardi N, Hutterer G, et al. Toxicities associated with the administration of So-rafenib, Sunitinib, and Temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol 2008; 53: 917–930.
- Mendel DB, Laird AD, Xin X, Christensen JG, Li G, Schrek RE, et al. In vivo antitumor activity of 5U11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a phar-macokinetic/pharmacodynamic relationship. Clin Cancer Res 2003; 9: 327–337.
- Azizi M, Chedid A, Oudard S. Home blood-pressure mon-itoring in patients receiving Sunitinib. N Engl J Med 2008; 358: 95–96.
- Chowdhunj S, Spicer J, Harper P. Hypertension and tar-geted therapy, part 2: small molecule inhibitors of VEGF. Tar-geted Oncol 2006; 1: 172–178.
- Houk BE, Bello CL, Michaelson MD, Bukowski RM, Red-man BG, Hudes GR, et al. Exposureresponse of sunitinib in metastatic renal cell carcinoma (mRCC): a population pharma-cokinetic/pharmacodynamic (PKPD) approach. J Clin Oncol 2007; 25 (Suppl 18): 241s.
- Mancia G, De Backer G, Dominiczak A, Cifkowa R, Fa-grad R, Germano G, et al. Management of arterial hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hy-pertension: The Task Force for the Management of Arterial Hy-pertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007; 25: 1105–87.
- Sica DA. Angiogenic inhibitors and hypertension: an emerging issue. J Clin Oncol 2006; 24: 1329–30.
- Khakoo AY, Kassiotis C, Tannir N, Plana JC, Halushka M, Bickford C, et al. Heart failure associated with sunitinib maleate. Cancer 2008; 10.1002/cbcr.23460.